Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) — The “Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The bioconjugation market is expected to grow to USD 10.86 billion by 2029, up from USD 5.27 billion in 2024, at a CAGR of 15.6% between 2024 and 2029.
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall bioconjugation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Several key factors impact the growth of the bioconjugation market. The development of targeted therapeutics such as ADCs is expected to be greatly supported by bioconjugation, as the need for more accurate and potent cancer treatments grows. Furthermore, there is a growing focus on technological developments and outsourcing services. Furthermore, emerging countries provide significant development opportunities, and the expanding applications of bioconjugation are expected to drive the market further.
Danaher Corporation (US); Lonza (Switzerland); Thermo Fisher Scientific Inc. (US); Merck KGaA (Germany); AbbVie Inc. (US); WuXi Biologics (Cayman) Inc. (China); Sartorius AG (Germany); are some of the key players in the bioconjugation market.
The antibody conjugation segment accounted for the largest share of by conjugation type segment for the bioconjugation services market in 2023.
In 2023, the antibody conjugation segment accounted for the largest share of the global bioconjugation services market by conjugation type. The antibody conjugation segment dominates the bioconjugation services market because it is widely used in developing targeted treatments, particularly for cancer.
Antibody-drug conjugates (ADCs) enable accurate drug delivery by targeting specific antigens on tumor cells, minimizing off-target effects and toxicity. The favourable results of ADCs in clinical trials, as well as their approval to treat a variety of malignancies, including HER2-positive breast cancer, have increased demand for antibody-based conjugation services.
The antibodies segment accounted for the largest share of by biomolecule type segment for the bioconjugation products market in 2023.
In 2023, the antibodies segment accounted for the largest share of the global bioconjugation products market by biomolecule type. The most prominent biomolecule type in the bioconjugation products market is antibodies, especially monoclonal antibodies, which are dominantly used in the development of Antibody-Drug Conjugates (ADCs) with higher accuracy in targeting.
Antibodies are integrally used in oncology and have led to several FDA-approved ADC therapies such as Adcetris and Kadcyla. These therapeutic antibodies conjugated with cytotoxic drugs through bioconjugation techniques allow for targeted treatment while minimizing systemic toxicity. Increasing clinical trials and FDA approvals for the drugs based on antibodies further drive the growth of this segment.
In 2023, the US remained to dominate the bioconjugation market.
The US dominated the North American bioconjugation market in 2023. The US is the world’s largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences.
Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, the growing prevalence of cancer is also driving the growth of the bioconjugation market.
The report provides insights on the following pointers:
- Analysis of key drivers (growing demand for targeted therapies, increasing investments in biopharmaceutical R&D, rising demand for outsourcing services, expanding pipeline of bioconjugated drugs, advancements in bioconjugation technologies), restraints (high cost of bioconjugate development & manufacturing, stringent regulatory requirements), opportunities (high growth potential of emerging economies, expanding applications of bioconjugation), and Challenges (technical complexities) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on newly launched products/services of the bioconjugation market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioconjugation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product/service offerings of leading players like Danaher Corporation (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), AbbVie Inc. (US), WuXi Biologics (Cayman) Inc. (China), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), among others in the market.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 677 |
| Forecast Period | 2024 – 2029 |
| Estimated Market Value (USD) in 2024 | $5.27 Billion |
| Forecasted Market Value (USD) by 2029 | $10.86 Billion |
| Compound Annual Growth Rate | 15.6% |
| Regions Covered | Global |
Companies Featured
- Danaher Corporation
- Lonza
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Abbvie Inc.
- Wuxi Biologics (Cayman) Inc.
- Sartorius AG
- Bio-Rad Laboratories, Inc.
- Catalent, Inc.
- Beckton, Dickinson and Company
- Agilent Technologies, Inc.
- Promega Corporation
- F. Hoffmann-La Roche Ltd.
- Charles River Laboratories
- Genscript Biotech Corporation
- Piramal Pharma Limited
- Abzena Ltd.
- New England Biolabs
- Biosynth
- Cell Signaling Technology, Inc.
- Creative Biolabs
- Formosa Laboratories Inc.
- Nj Bio, Inc.
- Rockland Immunochemicals, Inc.
- Shanghai Chempartner
- Sterling Pharma Solutions Limited
- Syngene International Limited
- Tokyo Chemical Industry Co. Ltd.
- Vector Laboratories, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/yedd0m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
